Experts convened in Cleveland, Ohio, on November 11, 2025, to discuss the evolution of cardio-renal-metabolic care from ...
Introducing Ozempic, a groundbreaking GLP-1 agonist now making waves in India! This innovative treatment emulates a natural ...
The ZENITH trial showed sotatercept significantly reduced death, transplant, or hospitalization risk in advanced PAH, leading ...
Denmark: Novo Nordisk and Akero Therapeutics have announced that Novo Nordisk's acquisition of Akero has been completed.With ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic ...
The FDA has qualified the first AI-based tool that can be used in clinical trials involving patients with metabolic ...
Altimmune, Inc. nears key MASH data for pemvidutide—learn investor risks, potential rewards, and what the upcoming results ...
Khaleej Times on MSN
Wegovy shows liver health benefits in MASH patients beyond weight loss
Novo Nordisk’s Wegovy® (semaglutide 2.4 mg) was associated with liver health–related benefits not solely driven by weight ...
This follows recent successful efforts by the Trump administration to cut the price of this compound for certain patients.
Zacks Investment Research on MSN
Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?
Novo Nordisk NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized ...
The U.S. has revealed price reductions for the second round of prescription drugs negotiated by the Centers for Medicare & Medicaid Services (CMS) through the Inflation Reduction Act (IRA). Headlining ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback